Grime, Dust and Duct Tape Found at J&J Plant

U.S. inspectors who toured the Johnson & Johnson plant at the center of last week's recall of widely used liquid children's products uncovered unsanitary conditions in at least one lab, according to a government report released on Tuesday.

The U.S. Food and Drug Administration (FDA) said in the report, dated April 30, that its inspectors found thick dust and grime covering certain equipment, a hole in the ceiling and duct tape-covered pipes at the Fort Washington, Penn., facility where 40 products recalled last Friday were made. Inspectors also found a lack of quality control procedures and poor handling of complaints, according to the report.

On Saturday, the FDA urged consumers to stop using liquid Tylenol, Motrin, Benadryl and Zyrtec for children and infants after a broad recall by Johnson & Johnson's consumer division late on Friday. Read the full list of more than 40 affected products made by McNeil Consumer Healthcare here.

McNeil said it was recalling the products in consultation with the FDA after discovering manufacturing deficiencies that could affect the quality, purity or potency of the medicines. On Tuesday, the FDA posted the inspection notice.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.